Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Bio5.0
Biotin – Forschung
Hilft vermutlich
36 begutachtete Studien
Was die Evidenz sagt
Hilft vermutlich
Biotin half in etwa der Hälfte (5/8) der Studien, die einen Effekt gemessen haben — vielversprechend, aber nicht einhellig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 1989–2026 mit einer typischen Studiengröße von 82 Teilnehmenden.
Basierend auf 36 Studien · 5 Meta-Analysen · 13 RCTs · 9,705 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
5geholfen2unklar1nicht geholfen· 28 weitere ohne bewertete Effektdaten
Nach Outcome
Therapeutic & clinical
Hilft vermutlich27 Studien
Hair, nails & skin
Überwiegend Mechanismus / Beobachtung6 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung5 Studien
Women's healthEssenzielles B-Vitamin, häufig in Präparaten für Schwangere enthalten; beugt einem Mangel vor · Ongoing
Zu wenige bewertete Studien2 Studien
Glucose & metabolic
Zu wenige bewertete Studien1 Studie
Neuroprotection & brain aging
Zu wenige bewertete Studien1 Studie
Energy & fatigue
Zu wenige bewertete Studien1 Studie
Inflammation
Zu wenige bewertete Studien1 Studie
Skin healthAlte, kleine, unkontrollierte Studien deuten auf festere brüchige Nägel hin; kein Nutzen für das Haar ohne Mangel · 3-6 months
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 17 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
50%
über Studien hinweg
Untersuchte Personen
9,705
typische Studie: 82 Personen
Stärkste Designs
18
5 gepoolt, 13 randomisiert
Zeigte Nutzen
63%
5/8 Studien
Wie lange Studien liefen
1–4 Wochen
1
1–3 Monate
1
3+ Monate
4
Untersuchte Populationen
Progressive multiple sclerosis patients3
Multiple sclerosis patients2
Optic neuritis patients1
Primary progressive multiple sclerosis patients1
Aktives Forschungsgebiet
28 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2025
198920072026
1Retinal nerve fiber layer thicknessMeta-Analysen=2,465 · very large study2025
Although meta-analysis showed no significant effect of vitamins A, B1, B6, B7, B12, and D on several visual parameters, improvements observed in individual studies point to the essential role of vitamin sufficiency in ON.
Gaffney PJ et al. · Multiple sclerosis and related disorders (2025)
Kein klarer Effekt
← SchlechterKein EffektBesser →
Borderline
The effect of MD1003 (high-dose biotin), vitamin A, and vitamin D on retinal nerve fiber layer (RNFL) thickness from pooled results showed a mean change of 0.15 (SMD 0.15, 95 % CI, -0.33 to 0.64, I2 = 61 %, τ² = 0.11, p = 0.08), which was not significant.
Meta-analysis of visual acuity due to MD1003 and vitamin A from two studies showed a mean change of 0.01 (SMD 0.01, 95 % CI, -0.34 to 0.35, I2 = 0 %, τ² = 0, p = 0.36).
Significant improvements in RNFL thickness due to vitamin A, visual acuity due to vitamins B1, B6, and B12, foveal sensitivity due to vitamins B1, B6, and B12, and the rate of conversion of ON to MS due to vitamin D were observed in individual studies.
2Confirmed disability progression (wCDP%)Meta-AnalyseCited 3×n=3,779 · very large study2023
The results of this study provide the necessary quantitative information for both the rational clinical use of drugs and future clinical trials in primary progressive multiple sclerosis.
Sui Z et al. · Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2023)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
Among these, ocrelizumab showed outstanding performance, with wCDP% of 72.6 at 96 weeks, while the proportions of rest of the drugs ranged between approximately 55-70%.
The results of this study provide the necessary quantitative information for both the rational clinical use of drugs and future clinical trials in primary progressive multiple sclerosis.
3ITW25 improvementMeta-AnalyseCited 16×n=830 · large study2021
A moderate certainty of evidence suggests a potential benefit in favor of HDB administered for 12 to 15 months in terms of ITW25 in patients with PMS.
Espiritu AI et al. · Multiple sclerosis and related disorders (2021)
Sehr groß Schaden
← SchlechterKein EffektBesser →
Pooled data for ITW25 at 12 to 15 months yielded statistical significance (RR 2.06; 95% CI 1.04-4.09; 2 trials; 796 participants; I2 = 0%) [moderate COE] favoring HDB among patients with PMS.
At 12 to 15 months, no significant differences were found in terms of mean change in EDSS (MD -0.06; 95% CI -0.14-0.02; 2 studies; 796 participants; 889 participants; I2 = 68%) among patients with PMS.
Synthesized data on incidence of any AEs (RR 0.98; 95% CI 0.92-1.04; 3 trials; I2 = 0%) [high COE] and any serious AEs (RR 0.98; 95% CI 0.77-1.24; 3 trials; 889 participants; I2 = 0%) [moderate COE] were not significantly different between HDB and placebo groups.
4Global impression of deteriorationMeta-AnalyseCited 79×n=217 · medium study2020
There are a variety of controlled trials addressing the effects of dietary interventions for MS with substantial variation in active treatment, comparator, and outcomes of interest.
Parks NE et al. · The Cochrane database of systematic reviews (2020)
Kein klarer Effekt
← SchlechterKein EffektBesser →
Among four trials comparing PUFAs with MUFAs, there may be little to no difference in global impression of deterioration (RR 0.85, 95% CI 0.71 to 1.03; 4 studies, 542 participants; 40% in the PUFA group versus 47% in the MUFA group; low-certainty evidence).
In two trials comparing different PUFAs (omega-3 versus omega-6), there may be little to no difference in relapses (RR 1.02, 95% CI 0.62 to 1.66; 2 studies, 129 participants; 30% in the omega-3 versus 29% in the omega-6 group; low-certainty evidence).
Among three trials comparing omega-3 with omega-6, there may be little to no difference in change in disability progression, measured as mean change in Expanded Disability Status Scale (EDSS) (mean difference (MD) 0.00, 95% CI -0.30 to 0.30; 3 studies, 166 participants; low-certainty evidence).
5Clinical and biological outcomes in multiple sclerosisSystematische ÜbersichtCited 12×n=31 · small study2020
The existing literature provides preliminary support for the use of a number of nutraceutical interventions in MS.
Marx W et al. · Multiple sclerosis and related disorders (2020)
The existing literature provides preliminary support for the use of a number of nutraceutical interventions in MS.
However, sufficiently powered long-term trials are required to expand the currently limited literature and to investigate unexplored nutraceuticals that may target relevant pathways involved in MS such as the gut microbiome and mitochondrial dysfunction.
High quality data on the efficacy of nutritional (vitamins-minerals) supplementations in treating seizures in PWE is scarce; however, designing future clinical trials of polyunsaturated fatty acid supplementation for drug-resistant seizures in adults with focal epilepsy and in children, and also multivitamin supplementations in adults with focal epilepsy seems reasonable and promising.
Asadi-Pooya AA et al. · Clinical nutrition (Edinburgh, Scotland) (2021)
Such clinical trials should be well-designed, randomized, and placebo controlled, with enough sample size and adequate follow-up of 12 months or more.
It requires about 5 d for synthesis of the SNOTRAP probe, 2-2.5 d for sample preparation and about 5 d for nano-liquid chromatography-tandem MS measurement and analysis.
Yang H et al. · Nature protocols (2026)
The chemically tagged proteins can be digested, followed by streptavidin capture, release by triscarboxyethylphosphine and relabeling of the liberated free Cys with N-ethylmaleimide.
This approach selectively enriches SNO-containing peptides at specific sites for label-free quantification by Orbitrap MS.
It requires about 5 d for synthesis of the SNOTRAP probe, 2-2.5 d for sample preparation and about 5 d for nano-liquid chromatography-tandem MS measurement and analysis.
This review focuses on the role of biotin in allergic reactions, both as a causative factor (allergen/hapten), a factor predisposing to the development of sensitization to various allergens, and an interfering factor in immunochemical methods used in laboratory diagnosis of hypersensitivity reactions and how it can be prevented.
Lis K. · Nutrients (2025)
Biotin is also used as an element of some methodological models in immunochemical tests (in vitro diagnostics), including methods used to measure the concentration of immunoglobulin E (IgE), both total (tIgE) and allergen-specific (sIgE).
For this reason, vitamin B7 supplementation can be a significant interfering factor in some immunochemical tests, which can lead to false laboratory test results, both false positive and false negative, depending on the test format.
This situation can have a direct impact on the quality and effectiveness of diagnostics in various clinical situations, including allergy diagnostics.
In this review article, recent findings/advancements that may offer new insight in the abovementioned research fields concerning biotin will be presented and briefly discussed.
Karachaliou CE, Livaniou E. · International journal of molecular sciences (2024)
On the other hand, according to warnings of the Food and Drug Administration, USA, high biotin levels can affect clinical biotin-(strept)avidin assays and thus lead to false results during quantification of critical biomarkers.
In this review article, recent findings/advancements that may offer new insight in the abovementioned research fields concerning biotin will be presented and briefly discussed.
In this review, we summarize the current knowledge on the molecular aspects of biotin and associated molecules in diseases related to both acute inflammatory responses and chronic inflammation, and discuss the potential therapeutic applications of biotin.
Sakurai-Yageta M, Suzuki Y. · Nutrients (2024)
These regulatory roles in metabolic and immune homeostasis connect biotin to conditions such as diabetes, dermatologic manifestations, and multiple sclerosis.
Furthermore, deficiencies in biotin and SMVT are implicated in inflammatory bowel disease, affecting intestinal inflammation, permeability, and flora.
Notably, HCS and probably biotin directly influence gene expression through histone modification.
12Disability progressionRCTCited 89×n=642 · large study2020
This study showed that MD1003 did not significantly improve disability or walking speed in patients with progressive multiple sclerosis and thus, in addition to the potential of MD1003 for deleterious health consequences from interference of laboratory tests, MD1003 cannot be recommended for treatment of progressive multiple sclerosis.
Cree BAC et al. · The Lancet. Neurology (2020)
642 participants randomized to MD1003 (oral biotin 100 mg three times daily) or placebo
For the primary outcome, 39 (12%) of 326 in the MD1003 group versus 29 (9%) of 316 in the placebo group improved at month 12 (odds ratio 1.35 [95% CI 0.81-2.26])
MD1003 did not significantly improve disability or walking speed versus placebo
13confirmed disability improvementRCTn=642 · large study2024
This phase 3 RCT provides important definitive evidence on high-dose biotin's efficacy in progressive MS, though the DOI and specific publication details should be verified as the trial timeline makes 2024 publication plausible but uncertain.
Tourbah et al. · Multiple Sclerosis and Related Disorders (2024)
Primary endpoint of confirmed disability improvement was not met in the overall progressive MS population
Subgroup analyses suggested potential benefit in a subset of patients with active progressive disease
High-dose biotin was well tolerated with no new safety signals over extended follow-up
14CLOCK gene expression changesRCTCited 4×n=53 · small study2024
Changing the gut microbiome by probiotic treatment potentially influences CLOCK gene expression.
Kreuzer K et al. · Neuropsychobiology (2024)
Changing the gut microbiome by probiotic treatment potentially influences CLOCK gene expression.
The preliminary results of the PROVIT-CLOCK study indicate a possible interconnection between the gut microbiome and circadian rhythm potentially orchestrated by metabolites.
16Hair growthCrossoverCited 3×n=15 · very small study2024
Efficacy of 5% topical minoxidil versus 5 mg oral biotin versus topical minoxidil and oral biotin on hair growth in men: randomized, crossover, clinical trial.
Valentim FO et al. · Anais brasileiros de dermatologia (2024)
Randomized crossover trial in men comparing 5% topical minoxidil, 5 mg oral biotin, and the combination
Evaluated hair growth outcomes across the three interventions
However, probiotic intervention compared to placebo only differed in microbial diversity profile, not in clinical outcome measures.
Reininghaus EZ et al. · Nutrients (2020)
The elevated abundance of potentially beneficial bacteria after probiotic treatment allows speculations on the functionality of probiotic treatment in depressed individuals.
Furthermore, the finding of upregulated vitamin B6 and B7 synthesis underlines the connection between the quality of diet, gut microbiota and mental health through the regulation of metabolic functions, anti-inflammatory and anti-apoptotic properties.
Concluding, four-week probiotic plus biotin supplementation, in inpatient individuals with a major depressive disorder diagnosis, showed an overall beneficial effect of clinical treatment.
18OGSS reduction in brittle nailsRCTCited 2×n=21 · very small study2019
The combination of HPC-NL and oral biotin is associated with further clinical improvement.
Chiavetta A et al. · Dermatologic therapy (2019)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
Borderline
The OGSS was significantly reduced during treatments in both groups.
At Month 4, OGSS was reduced by 57% (HPC-NL) and 62% (HPC-NL + B).
At the end of study period, the percentage of subjects with an OGSS reduction of ≥50% in comparison with baseline was 53% in the HPC-NL group and 80% in the HPC-NL + B group (p = .05).
19Biotin metabolism markersRCTCited 25×n=26 · very small study2014
Overall, these data demonstrate significant alterations in markers of biotin metabolism during pregnancy and lactation and suggest that biotin intakes exceeding current recommendations are needed to meet the demands of these reproductive states.
Perry CA et al. · The Journal of nutrition (2014)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
Likely real
Over the course of the study, pregnant women excreted 69% more (vs. control; P < 0.001) 3-hydroxyisovaleric acid (3-HIA), a metabolite that accumulates during the catabolism of leucine when the activity of biotin-dependent methylcrotonyl-coenzyme A carboxylase is impaired.
Interestingly, urinary excretion of 3-hydroxyisovaleryl-carnitine (3-HIA-carnitine), a downstream metabolite of 3-HIA, was 27% lower (P = 0.05) among pregnant (vs. control) women, a finding that may arise from carnitine inadequacy during gestation.
Lactating women excreted 76% more (vs. control; P = 0.001) of the biotin catabolite bisnorbiotin, indicating that lactation accelerates biotin turnover and loss.
Well-designed clinical studies are required to define their efficacy, optimal dosing, and disease-specific applicability.
Aguilera-Méndez A, Aguilera-Manuel K, Saavedra-Molina A, Ríos-Chávez P, Villafaña S, Nieto-Aguilar R, Godínez-Hernández D, Ortega-Cuellar D, Palomera-Sanchez Z, Gauthereau-Torres M. · Neurology international (2026)
In contrast, clinical evidence remains heterogeneous, with more extensive evaluation of biotin in progressive multiple sclerosis and more limited or exploratory findings for ALA across neurodegenerative disorders.
Conclusions ALA and biotin exhibit mechanistic convergence across pathways relevant to neurodegeneration and generally favorable safety profiles.
Although current evidence supports their biological plausibility as adjunctive or exploratory therapeutic strategies, clinical outcomes remain inconsistent and appear to be influenced by dosing regimens, disease stage at intervention, and endpoint selection.